Hypoxia-inducible factor 1 in tumor radioresistance

Current Signal Transduction Therapy

Volumn 5, Issue 3, 2010, Pages 188-196

  Harada, Hiroshi ^a   Hiraoka, Masahiro ^a  

^a KYOTO UNIVERSITY   (Japan)

Author keywords

Hypoxia inducible factor 1 (HIF 1); Radiation Therapy; Radioresistance; Reactive oxygen species; Reoxygenation; Ros; Tumor hypoxia; Tumor microenvironment

Indexed keywords

4 [BIS(2 CHLOROETHYL)OXIDOAMINO]PHENYLALANINE; ANTINEOPLASTIC AGENT; CISPLATIN; EVEROLIMUS; EZN 2968; GLYCERYL TRINITRATE; HYPOXIA INDUCIBLE FACTOR 1; HYPOXIA INDUCIBLE FACTOR 1ALPHA; NAVELBINE; PANOBINOSTAT; PROTEIN KINASE B; TOPOTECAN; UNCLASSIFIED DRUG; VASCULOTROPIN; VON HIPPEL LINDAU PROTEIN;

ADVANCED CANCER; ARTICLE; CANCER INHIBITION; CANCER RADIOTHERAPY; CANCER RESISTANCE; CLINICAL TRIAL; GENE EXPRESSION REGULATION; HUMAN; HYPOXIA; KIDNEY CANCER; LUNG ADENOCARCINOMA; LUNG NON SMALL CELL CANCER; NONHUMAN; OXYGEN CONSUMPTION; PRIORITY JOURNAL; PROGNOSIS; PROSTATE CANCER; RADIOSENSITIVITY; REOXYGENATION; SOLID TUMOR; STABLE ANGINA PECTORIS; TRANSCRIPTION REGULATION; TRANSLATION INITIATION; TUMOR REGRESSION; TUMOR VASCULARIZATION;

EID: 78650191972     PISSN: 15743624     EISSN: None     Source Type: Journal    
DOI: 10.2174/157436210791920229     Document Type: Article

References (73)

1. Mottram JC. Factor of importance in radiosensitivity of tumours. Br J Radiol 1936; 9: 606-14.
2. Gray LH, Conger AD, Ebert M, Hornsey S, Scott OC. The concentration of oxygen dissolved in tissues at the time of irradiation as a factor in radiotherapy. Br J Radiol 1953; 26: 638-48.
3. Thomlinson RH, Gray LH. The histological structure of some human lung cancers and the possible implications for radiotherapy. Br J Cancer 1955; 9: 539-49.
4. Kizaka-Kondoh S, Inoue M, Harada H, Hiraoka M. Tumor hypoxia: a target for selective cancer therapy. Cancer Sci 2003; 94: 1021-8.
5. Brown JM, Wilson WR. Exploiting tumour hypoxia in cancer treatment. Nat Rev Cancer 2004; 4: 437-47.
6. Hall EJ, Giaccia AJ, Eds, In: radiobiology for the radiobiologist. Sixth ed. Philadelphia: Lippincott Williams & Wilkins Co 2006.
7. Bristow RG, Hill RP. Hypoxia and metabolism. Hypoxia, DNA repair and genetic instability. Nat Rev Cancer 2008; 8: 180-92.
8. Bindra RS, Crosby ME, Glazer PM. Regulation of DNA repair in hypoxic cancer cells. Cancer Metastasis Rev 2007; 26: 249-60.
9. Semenza GL. HIF-1, O(2), and the 3 PHDs: how animal cells signal hypoxia to the nucleus. Cell 2001; 107: 1-3.
10. Hirota K, Semenza GL. Regulation of hypoxia-inducible factor 1 by prolyl and asparaginyl hydroxylases. Biochem Biophys Res Commun 2005; 338: 610-6.
11. Fukuda R, Hirota K, Fan F, Jung YD, Ellis LM, Semenza GL. Insulin-like growth factor 1 induces hypoxia-inducible factor 1- mediated vascular endothelial growth factor expression, which is dependent on MAP kinase and phosphatidylinositol 3-kinase signaling in colon cancer cells. J Biol Chem 2002; 277: 38205-11.
12. Fukuda R, Kelly B, Semenza GL. Vascular endothelial growth factor gene expression in colon cancer cells exposed to prostaglandin E2 is mediated by hypoxia-inducible factor 1. Cancer Res 2003; 63: 2330-4.
13. Zhong H, Chiles K, Feldser D, et al. Modulation of hypoxiainducible factor 1alpha expression by the epidermal growth factor/ phosphatidylinositol 3-kinase/PTEN/AKT/FRAP pathway in human prostate cancer cells: implications for tumor angiogenesis and therapeutics. Cancer Res 2000; 60: 1541-5.
14. Zundel W, Schindler C, Haas-Kogan D, et al. Loss of PTEN facilitates HIF-1-mediated gene expression. Genes Dev 2000; 14: 391-6.
15. Feldser D, Agani F, Iyer NV, Pak B, Ferreira G, Semenza GL. Reciprocal positive regulation of hypoxia-inducible factor 1alpha and insulin-like growth factor 2. Cancer Res 1999; 59: 3915-8.
16. Hellwig-Burgel T, Rutkowski K, Metzen E, Fandrey J, Jelkmann W. Interleukin-1beta and tumor necrosis factor-alpha stimulate DNA binding of hypoxia-inducible factor-1. Blood 1999; 94: 1561-7.
17. Zelzer E, Levy Y, Kahana C, Shilo BZ, Rubinstein M, Cohen B. Insulin induces transcription of target genes through the hypoxiainducible factor HIF-1alpha/ARNT. EMBO J 1998; 17: 5085-94.
18. 2+ signaling, prolyl hydroxylases, and mTOR. J Cell Physiol 2008; 217: 674-85.
19. 2+/calmodulin kinase-dependent activation of hypoxia inducible factor 1 transcriptional activity in cells subjected to intermittent hypoxia. J Biol Chem 2005; 280: 4321-8.
20. Semenza GL, Wang GL. A nuclear factor induced by hypoxia via de novo protein synthesis binds to the human erythropoietin gene enhancer at a site required for transcriptional activation. Mol Cell Biol 1992; 12: 5447-54.
21. Jelkmann W. Control of erythropoietin gene expression and its use in medicine. Methods Enzymol 2007; 435: 179-97.
22. Forsythe JA, Jiang BH, Iyer NV, et al. Activation of vascular endothelial growth factor gene transcription by hypoxia-inducible factor 1. Mol Cell Biol 1996; 16: 4604-13.
23. Semenza GL. Oxygen-dependent regulation of mitochondrial respiration by hypoxia-inducible factor 1. Biochem J 2007; 405: 1-9.
24. Fukuda R, Zhang H, Kim JW, Shimoda L, Dang CV, Semenza GL. HIF-1 regulates cytochrome oxidase subunits to optimize efficiency of respiration in hypoxic cells. Cell 2007; 129: 111-22.
25. Wood SM, Wiesener MS, Yeates KM, et al. Selection and analysis of a mutant cell line defective in the hypoxia-inducible factor-1 alpha- subunit (HIF-1alpha). Characterization of hif-1alphadependent and -independent hypoxia-inducible gene expression. J Biol Chem 1998; 273: 8360-8.
26. Semenza GL. Regulation of cancer cell metabolism by hypoxiainducible factor 1. Semin Cancer Biol 2009; 19: 12-6.
27. Zhang H, Bosch-Marce M, Shimoda LA, et al. Mitochondrial autophagy is an HIF-1-dependent adaptive metabolic response to hypoxia. J Biol Chem 2008; 283: 10892-903.
28. Semenza GL. Mitochondrial autophagy: life and breath of the cell. Autophagy 2008; 4: 534-6.
29. Wang GL, Jiang BH, Rue EA, Semenza GL. Hypoxia-inducible factor 1 is a basic-helix-loop-helix-PAS heterodimer regulated by cellular O2 tension. Proc Natl Acad Sci U S A 1995; 92: 5510-4.
30. Jaakkola P, Mole DR, Tian YM, et al. Targeting of HIF-alpha to the von Hippel-Lindau ubiquitylation complex by O2-regulated prolyl hydroxylation. Science 2001; 292: 468-72.
31. Berra E, Roux D, Richard DE, Pouyssegur J. Hypoxia-inducible factor-1 alpha (HIF-1 alpha) escapes O(2)-driven proteasomal degradation irrespective of its subcellular localization: nucleus or cytoplasm. EMBO Rep 2001; 2: 615-20.
32. Mahon PC, Hirota K, Semenza GL. FIH-1: a novel protein that interacts with HIF-1alpha and VHL to mediate repression of HIF-1 transcriptional activity. Genes Dev 2001; 15: 2675-86.
33. Laughner E, Taghavi P, Chiles K, Mahon PC, Semenza GL. HER2 (neu) signaling increases the rate of hypoxia-inducible factor 1alpha (HIF-1alpha) synthesis: novel mechanism for HIF-1- mediated vascular endothelial growth factor expression. Mol Cell Biol 2001; 21: 3995-4004.
34. Richard DE, Berra E, Gothie E, Roux D, Pouyssegur J. p42/p44 mitogen-activated protein kinases phosphorylate hypoxia-inducible factor 1alpha (HIF-1alpha) and enhance the transcriptional activity of HIF-1. J Biol Chem 1999; 274: 32631-7.
35. Sodhi A, Montaner S, Patel V, et al. The Kaposi's sarcomaassociated herpes virus G protein-coupled receptor up-regulates vascular endothelial growth factor expression and secretion through mitogen-activated protein kinase and p38 pathways acting on hypoxia- inducible factor 1alpha. Cancer Res 2000; 60: 4873-80.
36. Durand RE, Raleigh JA. Identification of nonproliferating but viable hypoxic tumor cells in vivo. Cancer Res 1998; 58: 3547-50.
37. Raleigh JA, Calkins-Adams DP, Rinker LH, et al. Hypoxia and vascular endothelial growth factor expression in human squamous cell carcinomas using pimonidazole as a hypoxia marker. Cancer Res 1998; 58: 3765-8.
38. Aebersold DM, Burri P, Beer KT, et al. Expression of hypoxiainducible factor-1alpha: a novel predictive and prognostic parameter in the radiotherapy of oropharyngeal cancer. Cancer Res 2001; 61: 2911-6.
39. Ishikawa H, Sakurai H, Hasegawa M, et al. Expression of hypoxicinducible factor 1alpha predicts metastasis-free survival after radiation therapy alone in stage IIIB cervical squamous cell carcinoma. Int J Radiat Oncol Biol Phys 2004; 60: 513-21.
40. Irie N, Matsuo T, Nagata I. Protocol of radiotherapy for glioblastoma according to the expression of HIF-1. Brain Tumor Pathol 2004; 21: 1-6.
41. Moeller BJ, Cao Y, Li CY, Dewhirst MW. Radiation activates HIF- 1 to regulate vascular radiosensitivity in tumors: role of reoxygenation, free radicals, and stress granules. Cancer Cell 2004; 5: 429-41.
42. Moeller BJ, Dreher MR, Rabbani ZN, et al. Pleiotropic effects of HIF-1 blockade on tumor radiosensitivity. Cancer Cell 2005; 8: 99-110.
43. Harada H, Itasaka S, Zhu Y, et al. Treatment regimen determines whether an HIF-1 inhibitor enhances or inhibits the effect of radiation therapy. Br J Cancer 2009; 100: 747-57.
44. Zhang X, Kon T, Wang H, et al. Enhancement of hypoxia-induced tumor cell death in vitro and radiation therapy in vivo by use of small interfering RNA targeted to hypoxia-inducible factor-1alpha. Cancer Res 2004; 64: 8139-42.
45. Gorski DH, Beckett MA, Jaskowiak NT, et al. Blockage of the vascular endothelial growth factor stress response increases the antitumor effects of ionizing radiation. Cancer Res 1999; 59: 3374-8.
46. Zeng L, Ou G, Itasaka S, et al. TS-1 enhances the effect of radiotherapy by suppressing radiation-induced hypoxia-inducible factor- 1 activation and inducing endothelial cell apoptosis. Cancer Sci 2008; 99: 2327-35.
47. Harada H, Itasaka S, Kizaka-Kondoh S, et al. The Akt/mTOR pathway assures the synthesis of HIF-1alpha protein in a glucoseand reoxygenation-dependent manner in irradiated tumors. J Biol Chem 2009; 284: 5332-42.
48. Li F, Sonveaux P, Rabbani ZN, et al. Regulation of HIF-1alpha stability through S-nitrosylation. Mol Cell 2007; 26: 63-74.
49. Ou G, Itasaka S, Zeng L, et al. Usefulness of HIF-1 imaging for determining optimal timing of combining bevacizumab and radiotherapy. Int J Radiat Oncol Biol Phys 2009; 75: 463-7.
50. Liu J, Qu R, Ogura M, Shibata T, Harada H, Hiraoka M. Real-time imaging of hypoxia-inducible factor-1 activity in tumor xenografts. J Radiat Res (Tokyo) 2005; 46: 93-102.
51. Harada H, Kizaka-Kondoh S, Hiraoka M. Optical imaging of tumor hypoxia and evaluation of efficacy of a hypoxia-targeting drug in living animals. Mol Imaging 2005; 4: 182-93.
52. Harada H, Kizaka-Kondoh S, Li G, et al. Significance of HIF-1- active cells in angiogenesis and radioresistance. Oncogene 2007; 26: 7508-16.
53. Harada H, Kizaka-Kondoh S, Itasaka S, et al. The combination of hypoxia-response enhancers and an oxygen-dependent proteolytic motif enables real-time imaging of absolute HIF-1 activity in tumor xenografts. Biochem Biophys Res Commun 2007; 360: 791-6.
54. Harada H, Xie X, Itasaka S, et al. Diameter of tumor blood vessels is a good parameter to estimate HIF-1-active regions in solid tumors. Biochem Biophys Res Commun 2008; 373: 533-8.
55. Dorie MJ, Kallman RF. Reoxygenation in the RIF-1 tumor. Int J Radiat Oncol Biol Phys 1984; 10: 687-93.
56. Murata R, Shibamoto Y, Sasai K, et al. Reoxygenation after single irradiation in rodent tumors of different types and sizes. Int J Radiat Oncol Biol Phys 1996; 34: 859-65.
57. Chandel NS, McClintock DS, Feliciano CE, et al. Reactive oxygen species generated at mitochondrial complex III stabilize hypoxiainducible factor-1alpha during hypoxia: a mechanism of O2 sensing. J Biol Chem 2000; 275: 25130-8.
58. Guzy RD, Hoyos B, Robin E, et al. Mitochondrial complex III is required for hypoxia-induced ROS production and cellular oxygen sensing. Cell Metab 2005; 1: 401-8.
59. Mansfield KD, Guzy RD, Pan Y, et al. Mitochondrial dysfunction resulting from loss of cytochrome c impairs cellular oxygen sensing and hypoxic HIF-alpha activation. Cell Metab 2005; 1: 393-9.
60. Griffiths JR, McSheehy PM, Robinson SP, et al. Metabolic changes detected by in vivo magnetic resonance studies of HEPA-1 wild-type tumors and tumors deficient in hypoxia-inducible factor- 1beta (HIF-1beta): evidence of an anabolic role for the HIF-1 pathway. Cancer Res 2002; 62: 688-95.
61. Goda N, Ryan HE, Khadivi B, McNulty W, Rickert RC, Johnson RS. Hypoxia-inducible factor 1alpha is essential for cell cycle arrest during hypoxia. Mol Cell Biol 2003; 23: 359-69.
62. Williams KJ, Telfer BA, Xenaki D, et al. Enhanced response to radiotherapy in tumours deficient in the function of hypoxiainducible factor-1. Radiother Oncol 2005; 75: 89-98.
63. Garcia-Barros M, Paris F, Cordon-Cardo C, et al. Tumor response to radiotherapy regulated by endothelial cell apoptosis. Science 2003; 300: 1155-9.
64. Folkman J, Merler E, Abernathy C, Williams G. Isolation of a tumor factor responsible for angiogenesis. J Exp Med 1971; 133: 275-88.
65. Folkman J. Tumor angiogenesis: therapeutic implications. N Engl J Med 1971; 285: 1182-6.
66. Greenberger LM, Horak ID, Filpula D, et al. A RNA antagonist of hypoxia-inducible factor-1alpha, EZN-2968, inhibits tumor cell growth. Mol Cancer Ther 2008; 7: 3598-608.
67. Welsh S, Williams R, Kirkpatrick L, Paine-Murrieta G, Powis G. Antitumor activity and pharmacodynamic properties of PX-478, an inhibitor of hypoxia-inducible factor-1alpha. Mol Cancer Ther 2004; 3: 233-44.
68. Koh MY, Spivak-Kroizman T, Venturini S, et al. Molecular mechanisms for the activity of PX-478, an antitumor inhibitor of the hypoxia-inducible factor-1alpha. Mol Cancer Ther 2008; 7: 90-100.
69. Rapisarda A, Uranchimeg B, Scudiero DA, et al. Identification of small molecule inhibitors of hypoxia-inducible factor 1 transcriptional activation pathway. Cancer Res 2002; 62: 4316-24.
70. Rapisarda A, Zalek J, Hollingshead M, et al. Schedule-dependent inhibition of hypoxia-inducible factor-1alpha protein accumulation, angiogenesis, and tumor growth by topotecan in U251-HRE glioblastoma xenografts. Cancer Res 2004; 64: 6845-8.
71. Yasuda H, Nakayama K, Watanabe M, et al. Nitroglycerin treatment may enhance chemosensitivity to docetaxel and carboplatin in patients with lung adenocarcinoma. Clin Cancer Res 2006; 12: 6748-57.
72. Kim MS, Kwon HJ, Lee YM, et al. Histone deacetylases induce angiogenesis by negative regulation of tumor suppressor genes. Nat Med 2001; 7: 437-43.
73. Abraham RT. mTOR as a positive regulator of tumor cell responses to hypoxia. Curr Top Microbiol Immunol 2004; 279: 299-319.